Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1
* Ovarian, Fallopian Tube or Primary Peritoneal cancer of serous histology
* Incurable cancer
* Willingness to provide paraffin-embedded tissue blocks of ovarian cancer
* Measurable disease
* Obtained =\< 14 days prior to registration: Absolute neutrophil count (ANC) \>= 1500 uL
* Obtained =\< 14 days prior to registration: Platelet (PLT) \>= 100,000 uL
* Obtained =\< 14 days prior to registration: Hemoglobin (Hgb) \>= 9 g/dL
* Obtained =\< 14 days prior to registration: Total bilirubin =\< 1.5 x upper limit of normal (ULN) or direct bilirubin =\< ULN
* Obtained =\< 14 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 3 x ULN or SGOT (AST) and SGPT (ALT) =\< 5 x ULN is acceptable if liver has tumor involvement
* Obtained =\< 14 days prior to registration: Creatinine =\< 1.5 x ULN
* Obtained =\< 14 days prior to registration: Fasting serum glucose =\< 1.5 x ULN
* Obtained =\< 14 days prior to registration: Total cholesterol =\< 1.5 x ULN
* Obtained =\< 14 days prior to registration: Triglycerides =\< 1.5 x ULN
* Life expectancy \>= 12 weeks

Exclusion Criteria:

* Platinum-sensitive disease (exceptions allowed: patient has had a hypersensitivity reaction to platinum or the treating oncologist thinks that further platinum therapy is not in the patient?s best interest)
* Morbidities or concurrent major illness (for example, bowel obstruction or a second active malignancy) that, in the opinion of the treating healthcare provider, would make participation in the trial problematic
* Leptomeningeal disease or uncontrolled brain metastasis
* Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment

  * NOTE: Patients can have peripheral (sensory) neuropathy
* History of hypertriglyceridemia or hypercholesterolemia and currently on medication(s)
* Use of St. John?s wort =\< 7 days prior to registration
* Unable to discontinue use of a strong CYP3A4 inhibitor